Tumor-associated thrombosis
Thieme. All rights reserved..
The evidence available today from randomized controlled trials shows that for many patients with CAT, direct FXa-inhibitors are a safer and potentially more effective therapy than long-term treatment with Low Molecular Weight Heparin (LMWH), which has been the gold standard. Oral therapy should be used with caution, particularly in the case of gastrointestinal or urothelial tumors, especially if the tumor is still in situ. Even with LMWH there is an increased risk of bleeding. Although no randomized studies are available yet, for selected stable patients, a dose reduction for secondary prophylaxis after 6 months can represent an alternative with a relatively low risk of bleeding - an individual benefit-risk assessment is essential. Incidental VTE are anticoagulated according to the guidelines according to the standard. A less intensive AK may be justifiable in individual cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:148 |
|---|---|
| Enthalten in: |
Deutsche medizinische Wochenschrift (1946) - 148(2023), 17 vom: 07. Sept., Seite 1070-1074 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Tumorassoziierte Thrombose |
|---|
| Beteiligte Personen: |
Bauersachs, Rupert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
English Abstract |
|---|
| Anmerkungen: |
Date Completed 25.08.2023 Date Revised 06.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1941-7132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36110006X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36110006X | ||
| 003 | DE-627 | ||
| 005 | 20231226084428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-1941-7132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM36110006X | ||
| 035 | |a (NLM)37611569 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Bauersachs, Rupert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor-associated thrombosis |
| 246 | 3 | 3 | |a Tumorassoziierte Thrombose |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2023 | ||
| 500 | |a Date Revised 06.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a The evidence available today from randomized controlled trials shows that for many patients with CAT, direct FXa-inhibitors are a safer and potentially more effective therapy than long-term treatment with Low Molecular Weight Heparin (LMWH), which has been the gold standard. Oral therapy should be used with caution, particularly in the case of gastrointestinal or urothelial tumors, especially if the tumor is still in situ. Even with LMWH there is an increased risk of bleeding. Although no randomized studies are available yet, for selected stable patients, a dose reduction for secondary prophylaxis after 6 months can represent an alternative with a relatively low risk of bleeding - an individual benefit-risk assessment is essential. Incidental VTE are anticoagulated according to the guidelines according to the standard. A less intensive AK may be justifiable in individual cases | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Deutsche medizinische Wochenschrift (1946) |d 1946 |g 148(2023), 17 vom: 07. Sept., Seite 1070-1074 |w (DE-627)NLM000002852 |x 1439-4413 |7 nnns |
| 773 | 1 | 8 | |g volume:148 |g year:2023 |g number:17 |g day:07 |g month:09 |g pages:1070-1074 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1941-7132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 148 |j 2023 |e 17 |b 07 |c 09 |h 1070-1074 | ||